Stocks and Investing
Stocks and Investing
Fri, November 5, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, November 4, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gil Blum Maintained (SRPT) at Strong Buy with Decreased Target to $157 on, Nov 4th, 2021
Gil Blum of Needham, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Decreased Target from $166 to $157 on, Nov 4th, 2021.
Gil has made no other calls on SRPT in the last 4 months.
There are 6 other peers that have a rating on SRPT. Out of the 6 peers that are also analyzing SRPT, 3 agree with Gil's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Judah Frommer of "Credit Suisse" Maintained at Hold with Decreased Target to $95 on, Friday, October 15th, 2021
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $90 on, Monday, August 16th, 2021
- Anupam Rama of "JP Morgan" Upgraded from Sell to Hold and Decreased Target to $87 on, Thursday, August 5th, 2021
These are the ratings of the 3 analyists that currently disagree with Gil
- Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $125 on, Tuesday, October 12th, 2021
- Whitney Ijem of "Guggenheim" Upgraded from Hold to Strong Buy on, Wednesday, September 15th, 2021
- Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $122 on, Thursday, August 5th, 2021
Contributing Sources